Published in BMC Cancer on March 17, 2007
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer (2010) 1.63
Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta Orthop (2011) 1.29
Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08
Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. Sarcoma (2010) 1.03
Raman spectroscopy in biomedicine - non-invasive in vitro analysis of cells and extracellular matrix components in tissues. Biotechnol J (2012) 1.00
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis. Cancer Cell Int (2010) 0.80
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol (2010) 0.79
Current advances in animal model of chondrosarcoma and related research. Biomed Rep (2012) 0.76
Mechanisms of angiogenesis and arteriogenesis. Nat Med (2000) 13.88
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg (1972) 4.37
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J (2003) 3.62
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 3.35
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res (2000) 2.39
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays (1991) 1.93
Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res (2005) 1.62
Signal transduction by fibroblast growth factor receptors. Front Biosci (1999) 1.61
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res (2003) 1.53
Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J (2002) 1.51
Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors (1999) 1.43
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res (2002) 1.40
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J (2002) 1.28
Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res (2005) 1.19
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res (2004) 1.18
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys (2004) 1.05
Anticancer drug targets: approaching angiogenesis. J Clin Invest (1999) 0.98
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer (2006) 0.97
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer (2005) 0.96
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res (2003) 0.96
Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets (2003) 0.96
Resistance to anti-VEGF agents. Curr Pharm Des (2004) 0.82
A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim (2005) 0.80
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 2.25
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Cartilage-like gene expression in differentiated human stem cell spheroids: a comparison of bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum (2003) 1.84
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res (2005) 1.62
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res (2003) 1.53
A new concept for interactive radiotherapy planning with multicriteria optimization: first clinical evaluation. Radiother Oncol (2007) 1.45
Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res (2011) 1.42
MicroRNA expression after ionizing radiation in human endothelial cells. Radiat Oncol (2010) 1.38
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res (2008) 1.36
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res (2003) 1.35
The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med (2002) 1.35
Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res (2009) 1.35
CT-guided radiofrequency ablation of osteoid osteoma and osteoblastoma: clinical success and long-term follow up in 77 patients. Eur J Radiol (2012) 1.30
18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med (2004) 1.29
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol (2012) 1.28
Megaprostheses for the treatment of malignant bone tumours of the lower limbs. Int Orthop (2006) 1.27
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials (2009) 1.24
Survival of the cementless Spotorno stem in the second decade. Clin Orthop Relat Res (2009) 1.24
LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res (2012) 1.20
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A (2013) 1.20
Cementless Spotorno tapered titanium stems: excellent 10-15-year survival in 141 young patients. Acta Orthop Scand (2003) 1.18
4D-MRI analysis of lung tumor motion in patients with hemidiaphragmatic paralysis. Radiother Oncol (2009) 1.13
Uncemented grit-blasted straight tapered titanium stems in patients younger than fifty-five years of age. Fifteen to twenty-year results. J Bone Joint Surg Am (2009) 1.11
Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther (2009) 1.09
Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer (2010) 1.09
Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther (2008) 1.09
Signs of reperfusion injury following CO2 pneumoperitoneum: an in vivo microscopy study. Surg Endosc (2007) 1.08
Computed tomography monitoring of radiation-induced lung fibrosis in mice. Invest Radiol (2004) 1.08
Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat (2005) 1.07
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys (2010) 1.07
Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys (2005) 1.06
Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J (2009) 1.06
Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett (2008) 1.05
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys (2004) 1.05
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia (2011) 1.04
Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. Am J Physiol Lung Cell Mol Physiol (2007) 1.04
Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol (2008) 1.03
Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol (2009) 1.03
Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer (2010) 1.02
Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull base. Cancer (2009) 1.02
Therapy monitoring using dynamic MRI: analysis of lung motion and intrathoracic tumor mobility before and after radiotherapy. Eur Radiol (2006) 1.00
Intercellular communication by exchange of cytoplasmic material via tunneling nano-tube like structures in primary human renal epithelial cells. PLoS One (2011) 1.00
Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer (2007) 1.00
Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One (2012) 0.99
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol (2011) 0.99
Application of constant vs. variable relative biological effectiveness in treatment planning of intensity-modulated proton therapy. Int J Radiat Oncol Biol Phys (2010) 0.98
Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer (2011) 0.98
Apoptosis signals in lymphoblasts induced by focused ultrasound. FASEB J (2004) 0.98
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer (2006) 0.97
Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature. Radiat Oncol (2010) 0.96
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol (2010) 0.95
Identification of drug-regulated genes in osteosarcoma cells. Int J Cancer (2003) 0.95
Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. Am J Pathol (2010) 0.95
Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas. Int J Radiat Oncol Biol Phys (2010) 0.94
High survival in young patients using a second generation uncemented total hip replacement. Int Orthop (2011) 0.94
Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol (2006) 0.94
Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis. BMC Cancer (2012) 0.93
Hepatic platelet and leukocyte adherence during endotoxemia. Crit Care (2006) 0.92
CT-guided radiofrequency ablation of osteoid osteoma: correlation of clinical outcome and imaging features. Diagn Interv Radiol (2013) 0.92
Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. J Cancer Res Clin Oncol (2004) 0.92
Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol (2010) 0.92
Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. Neoplasia (2009) 0.91
Engineering cell-fluorescent ion track hybrid detectors. Radiat Oncol (2013) 0.91
Long-term fate of uncemented, threaded acetabular components with smooth surface treatment: minimum 10-year follow-up of two different designs. Arch Orthop Trauma Surg (2004) 0.91
Biological in-vivo measurement of dose distribution in patients' lymphocytes by gamma-H2AX immunofluorescence staining: 3D conformal- vs. step-and-shoot IMRT of the prostate gland. Radiat Oncol (2011) 0.91
Bronchial artery revascularization affects graft recovery after lung transplantation. Am J Respir Crit Care Med (2002) 0.90
Proton irradiation suppresses angiogenic genes and impairs cell invasion and tumor growth. Radiat Res (2012) 0.90
Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer. Radiat Oncol (2011) 0.90
IGRT versus non-IGRT for postoperative head-and-neck IMRT patients: dosimetric consequences arising from a PTV margin reduction. Radiat Oncol (2012) 0.90
Prospective identification of glioblastoma cells generating dormant tumors. PLoS One (2012) 0.90
A clinical concept for interfractional adaptive radiation therapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 0.90
Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys (2005) 0.90
A reproducible and simple grading system for classical chondrosarcomas. Analysis of 35 chondrosarcomas and 16 enchondromas with emphasis on recurrence rate and radiological and clinical data. Virchows Arch (2003) 0.88
Clinical and prognostic role of annexin A2 in multiple myeloma. Blood (2012) 0.88
Subcellular spatial correlation of particle traversal and biological response in clinical ion beams. Int J Radiat Oncol Biol Phys (2013) 0.88